OBJECTIVES: Integration of pharmacogenomics into clinical care is being studied in multiple disciplines. We hypothesized that understanding attitudes and perceptions of anesthesiologists, critical care and pain medicine providers would uncover unique considerations for future implementation within perioperative care. METHODS: A survey (multiple choice and Likert-scale) was administered to providers within our Department of Anesthesia and Critical Care prior to initiation of a department-wide prospective pharmacogenomics implementation program. The survey addressed knowledge, perceptions, experiences, resources and barriers. RESULTS: Of 153 providers contacted, 149 (97%) completed the survey. Almost all providers (92%) said that genetic results influence drug therapy, and few (22%) were skeptical about the usefulness of pharmacogenomics. Despite this enthusiasm, 87% said their awareness about pharmacogenomic information is lacking. Feeling well-informed about pharmacogenomics was directly related to years in practice/experience: only 38% of trainees reported being well-informed, compared to 46% of those with 1-10 years of experience, and nearly two-thirds with 11+ years (P < 0.05). Regarding barriers, providers reported uncertainty about availability of testing, turnaround time and whether testing is worth financial costs. CONCLUSIONS: Anesthesiology, critical care and pain medicine providers are optimistic about the potential clinical utility of pharmacogenomics, but are uncertain about practical aspects of testing and desire clear guidelines on the use of results. These findings may inform future institutional efforts toward greater integration of genomic results to improve medication-related outcomes.
OBJECTIVES: Integration of pharmacogenomics into clinical care is being studied in multiple disciplines. We hypothesized that understanding attitudes and perceptions of anesthesiologists, critical care and pain medicine providers would uncover unique considerations for future implementation within perioperative care. METHODS: A survey (multiple choice and Likert-scale) was administered to providers within our Department of Anesthesia and Critical Care prior to initiation of a department-wide prospective pharmacogenomics implementation program. The survey addressed knowledge, perceptions, experiences, resources and barriers. RESULTS: Of 153 providers contacted, 149 (97%) completed the survey. Almost all providers (92%) said that genetic results influence drug therapy, and few (22%) were skeptical about the usefulness of pharmacogenomics. Despite this enthusiasm, 87% said their awareness about pharmacogenomic information is lacking. Feeling well-informed about pharmacogenomics was directly related to years in practice/experience: only 38% of trainees reported being well-informed, compared to 46% of those with 1-10 years of experience, and nearly two-thirds with 11+ years (P < 0.05). Regarding barriers, providers reported uncertainty about availability of testing, turnaround time and whether testing is worth financial costs. CONCLUSIONS: Anesthesiology, critical care and pain medicine providers are optimistic about the potential clinical utility of pharmacogenomics, but are uncertain about practical aspects of testing and desire clear guidelines on the use of results. These findings may inform future institutional efforts toward greater integration of genomic results to improve medication-related outcomes.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Brittany A Borden; Paige Galecki; Rebecca Wellmann; Keith Danahey; Sang Mee Lee; Linda Patrick-Miller; Matthew J Sorrentino; Rita Nanda; Jay L Koyner; Tamar S Polonsky; Walter M Stadler; Cathleen Mulcahy; Robert T Kavitt; Mark J Ratain; David O Meltzer; Peter H O'Donnell Journal: Pharmacogenet Genomics Date: 2019-02 Impact factor: 2.089
Authors: Nataša Karas Kuželički; Irena Prodan Žitnik; David Gurwitz; Adrian Llerena; Ingolf Cascorbi; Sofia Siest; Maurizio Simmaco; Marc Ansari; Mario Pazzagli; Chiara Di Resta; Ivan Brandslund; Matthias Schwab; Pieter Vermeersch; Jeantine E Lunshof; George Dedoussis; Christodoulos S Flordellis; Uwe Fuhr; Julia C Stingl; Ron Hn van Schaik; Vangelis G Manolopoulos; Janja Marc Journal: Pharmacogenomics Date: 2019-06 Impact factor: 2.533
Authors: Peter H O'Donnell; Keith Danahey; Michael Jacobs; Nisha R Wadhwa; Shennin Yuen; Angela Bush; Yasmin Sacro; Matthew J Sorrentino; Mark Siegler; William Harper; Andrea Warrick; Soma Das; Don Saner; Christopher L Corless; Mark J Ratain Journal: Am J Med Genet C Semin Med Genet Date: 2014-03-10 Impact factor: 3.908
Authors: Tien M Truong; Jeffrey Apfelbaum; Sajid Shahul; Magdalena Anitescu; Keith Danahey; Randall W Knoebel; David Liebovitz; Theodore Karrison; Xander M R van Wijk; Kiang-Teck J Yeo; David Meltzer; Mark J Ratain; Peter H O'Donnell Journal: Clin Pharmacol Ther Date: 2019-08-21 Impact factor: 6.875